Gain Therapeutics Statistics
Total Valuation
GANX has a market cap or net worth of $40.86 million. The enterprise value is $31.11 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GANX has 25.54 million shares outstanding. The number of shares has increased by 61.24% in one year.
| Current Share Class | 25.54M |
| Shares Outstanding | 25.54M |
| Shares Change (YoY) | +61.24% |
| Shares Change (QoQ) | +38.07% |
| Owned by Insiders (%) | 5.09% |
| Owned by Institutions (%) | 6.68% |
| Float | 24.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 94.96 |
| PB Ratio | 4.84 |
| P/TBV Ratio | 4.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.99, with a Debt / Equity ratio of 0.09.
| Current Ratio | 2.99 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -263.14% and return on invested capital (ROIC) is -148.43%.
| Return on Equity (ROE) | -263.14% |
| Return on Assets (ROA) | -94.12% |
| Return on Capital (ROIC) | -148.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$667,717 |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GANX has paid $46,579 in taxes.
| Income Tax | 46,579 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.52% in the last 52 weeks. The beta is 0.34, so GANX's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -38.52% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 2.43 |
| Relative Strength Index (RSI) | 36.02 |
| Average Volume (20 Days) | 285,422 |
Short Selling Information
The latest short interest is 658,341, so 2.58% of the outstanding shares have been sold short.
| Short Interest | 658,341 |
| Short Previous Month | 572,006 |
| Short % of Shares Out | 2.58% |
| Short % of Float | 2.72% |
| Short Ratio (days to cover) | 1.65 |
Income Statement
| Revenue | n/a |
| Gross Profit | -8.60M |
| Operating Income | -21.43M |
| Pretax Income | -21.54M |
| Net Income | -21.37M |
| EBITDA | -21.36M |
| EBIT | -21.43M |
| Earnings Per Share (EPS) | -$1.08 |
Full Income StatementBalance Sheet
The company has $12.05 million in cash and $769,413 in debt, giving a net cash position of $11.28 million or $0.44 per share.
| Cash & Cash Equivalents | 12.05M |
| Total Debt | 769,413 |
| Net Cash | 11.28M |
| Net Cash Per Share | $0.44 |
| Equity (Book Value) | 8.91M |
| Book Value Per Share | 0.34 |
| Working Capital | 9.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.08 million and capital expenditures -$21,567, giving a free cash flow of -$21.10 million.
| Operating Cash Flow | -21.08M |
| Capital Expenditures | -21,567 |
| Free Cash Flow | -21.10M |
| FCF Per Share | -$0.83 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |